Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
AstraZeneca's Imfinzi, combined with chemo, improves survival in early-stage gastric cancer, study shows.
AstraZeneca's drug Imfinzi, when combined with standard chemotherapy, has shown improved event-free survival in early-stage gastric cancer patients, according to the MATTERHORN Phase III trial.
The drug also showed a strong trend for better overall survival.
Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million annual diagnoses.
The treatment's safety profile aligns with known risks, and the results will be shared at a medical conference and with regulators.
8 Articles
Imfinzi de AstraZeneca, combinado con quimio, mejora la supervivencia en cáncer gástrico en estadio temprano, según muestra el estudio.